Reddit Posts
Altimmune and Viking are the last two companies left for Pharma to FOMO into the Obesity market
Altimmune and Viking are the last two companies left for Pharma to FOMO into the Obesity market
7 Diabetes and Weight Loss Drug Stocks With Big Potential
VIKING therapeutics VKTX trying to go high.. seeing unusual call activities..
VKTX yesterday there was high unusual call activities there must be something nrws, it can spike to the new high..
VKTX lot of unusual call activity(half million twice) today, there must be something, get into this guys..
Viking stock jumps on early-stage data for obesity drug (NASDAQ:VKTX)
I Told You Guys Early On We Were In For A Treat From The Healthcare Sector 📈 Only 2 Stocks With Trading Plans Posted Today In The Chatroom ✌️ $VKTX $BMEA Not 10 - 20 Stocks ❌ Both Stocks Closed Green After Hours Making New Highs ✔️ This Is Why We Have The #1 Chatroom For Breakout Alerts 🚨
I Told You Guys Early On We Were In For A Treat From The Healthcare Sector 📈 Only 2 Stocks With Trading Plans Posted Today In The Chatroom ✌️ $VKTX $BMEA Not 10 - 20 Stocks ❌ Both Stocks Closed Green After Hours Making New Highs ✔️ This Is Why We Have The #1 Chatroom For Breakout Alerts 🚨
$VKTX The Original Trade Alert Before The Trading Plan 7:08 AM 🚨 A Little Early For Most ☀️ ☕️ 3 Trading Plans In Total On This Play Alone Today , $13.88 Entry By Far The Best ✔️
$VKTX The Original Trade Alert Before The Trading Plan 7:08 AM 🚨 A Little Early For Most ☀️ ☕️ 3 Trading Plans In Total On This Play Alone Today , $13.88 Entry By Far The Best
$VKTX Started The Morning Superb 😃 After The Bell We Needed A Gap Fill 😴 Very Low Range With Each Candle 😴 The Price Action Isn’t Bad But The Range Is Very Low 😴 $BMEA $ITCI $OSCR $SPY
$VKTX Started The Morning Superb 😃 After The Bell We Needed A Gap Fill 😴 Very Low Range With Each Candle 😴 The Price Action Isn’t Bad But The Range Is Very Low 😴 $BMEA $ITCI $OSCR $SPY
VKTX$ Viking Therapeutics - Thoughts on this stocks?
VKTX$ Viking Therapeutics - Looking for thoughts/ideas
VKTX is on the rise !! 🛸🛸🛸 support this life changing company 🤔🤔
Mentions
I like biotech stocks or ETFs. One of the last high growth areas that hasn’t recovered. Names like NTLA VKTX GPCR still have lots of room to grow and AI is going to make everything cheaper and more efficient for doing research.
That's normal for calls that are far into the future. Look at Jan 27 AAPL calls or BIIB (same industry as VKTX) calls. The 30 calls have the highest open interest of the series, so that's probably what everyone else is buying to do the same thing you are doing. However, if you are going for outright stock replacement, forget about delta. Look at the bid and decide what leverage factor you want. For example, the 15 calls are bidding $20. If you were to buy shares at the current $32.85, you'd pay $3285, but the call only costs $2000, so that's 1.5x leverage. That's not quite right, since you only have a delta-weighted share of that equity with the call, not the full 100%, but close enough to ballpark estimate.
Gonna make money being regarded with VKTX now
VKTX, hopefully My bags are heavy but I strongly think it will be acquired for its weight loss drug that’s showing top of class results. It’s been going up the last weeks thank god
i think your sentiment is right. definitely not competing (hence why i feel safe-ish holding both). VK2735 is a better pure weightloss drug, but Pemvi looks increasingly like a great all-in-one solution for multiple indications (also with incredibly good tolerance on par with VK2735) which i think might make it more likely BO target in the short term than VKTX. Since Alt cash runway is very short, i'm expecting news to this tune by EoY. tendies crossed.
Fundamentals are bad, technically it was okay. VKTX is the opposite, very great fundamentals which is why I made this DD.
They're not competing, I don't think Altimmune will work out long term. We never know though but I definitely am not bullish like I am with VKTX.
With result news drops for $IXHL potentially this Sunday and for $REPL next Tuesday. I hope I can use most of that profit to disburse between $CTM and $VKTX
I'd say start at looking at the Phase 1 oral data last year. The data, while small, showed placebo like tolerability -- an absolute game change amongst obesity drugs currently on the market and in any clincial trials. The upcoming phase 2 data has an even more conservative dosing schedule, which means there is even more reason to expect tolerability will be fantastic again, which would clearly establish VKTX's best in class profile in the largest TAM in history.
I'm not OP, but I have 10k of VKTX and have made six figures trading this stock multiple times since 2018. Every clinical biotech inherently has risks, but this is the single most derisked stocks in the field I have ever encountered. I almost posted my $700k gains here last year but I'm looking for my first 7 figure trade here based on the oral data readout in the next 3-6 weeks. Maybe I'll post that if it comes to fruition.
The fact that $VKTX can offer potential oral and monthly maintenance after SC with the same molecule is not to be underestimated. Even $LLy does not have that. It is uncertain how people will react when switching from TP to orfoglipron.. large pharma eyes on that as almost everyone there is talking about need for solutions for long-term adherence beyond 1-2 years. Listen to $ABBV $PFE and others. Don’t believe $NVO semaglutide is competitive with that Viking only needs to show that small dose oral has any activity in phase 2 in a few weeks
You should add that, while $VKTX is held by 70% institutions, it is also massively shorted (~28M short on ~112M shares O/S). There isn't sufficient retail awareness to squeeze the shorts - many of which are the same 'tutes holding long positions. It'd be awesome to launch a WSB counterattack to rout the shorts, force them to cover, and catapult the SP by 10x or more.
VKTX viking pharmaceuticals likely has the best in class of the next generation of weight loss drugs with oral option to rival Lily’s terzepatide. The subq version is in phase 3 and data is due out in the next month or so for the phase 2 oral version. Huge growing market as these glp1/gip drugs are being found to help with so many serious health issues. Stock has also has huge short interest as biotech often get shorted to oblivion during data desert periods. If all goes well their drugs should be hitting the market in 2029.
It doesn't matter, I'm not even really bullish on that micro-cap, I just couldn't keep it out of the screenshot because I wanted the column names to be there so I had to put a big gray block on top of it. What I am bullish on is VKTX.
??????????? Semaglutide is old news, in fact it's losing a ton of market share to tirzepatide and the next-gen (dual GLP-GIP, while semaglutide is GLP only). Look at NVO's semaglutide revenue vs LLY's tirzepatide revenue YoY and their respective growth. NVO is massively down for a reason. There's not much hope for them left, they may keep 5-10% of the TAM long term, but LLY will be #1 and VKTX may be #2-3.
Spot on. Another very big reason is because VKTX was, at that point, entering a data desert period, which is pretty much always a negative thing for biotech stocks' share price.
I just sold 25% of my MDGL and 25% of my ROKU. Then I added some to my DECK position. I sold a lot more than I added, today. Recently, I sold all my SHAK and all my GOOS (I bought earlier in 2025). If VKTX, Z, and RDDT go up, I'll start to reduce my positions, and add some to my crushed positions (DECK and VFC). I add shares, when stocks drop. I shed shares, when they retrace upward.
Trading the latest news (in AI and mineral deals, for example) is not an edge. Be early, not late. VKTX
Yes. Do it. Buy VKTX, but don’t listen to random people on Reddit. Do you own research.
i bought VKTX leaps and im down a lot so i need this shit to pump 🙄
Names? Im in SANA, VKTX and BNTC
AAPL, AMZN, VKTX, NIO calls
VKTX. GLP 1 Weight loss trial data any day now. Heavy short interest.🚀
VKTX. Two data readouts in the next 2 years.
VKTX maybe. But I made money on them before I lost some and then sold. I’m still at my cost basis on CLOV. Maybe HUMA is the only one where I’m “down” but my new cost basis is around their current SP and I’m very bullish going forward so i don’t consider it a “loss” unless I’ve abandoned the position. ASML ironically (the darling of r/valueinvesting) may be my only big loser where I definitely lost money and never went back or DCAed down. And they’re still sideways since then lol. I opened small positions in a few companies based on very little DD and regretted it: LODE, RIME, etc. they weren’t high-conviction picks though. Ohh also remembered another winner. Got into RR at less than $1. Had a CB of like $.75, sold a lot at $4-5 and I’ll buy some more here and there below $2.
VKTX and SANA will make me a tendiful man.
QXO and VKTX will both do great in the next 1-3 years.
what do we think of Viking Therapeutics (VKTX)?
With ROKU, I'm currently at break even, after 16 months of holding it. It's within 1 dollar of where I bought it (over several days, back in Feb 2024). I'm up some on PYPL and some on Z. But I'm down on VKTX and DECK. I knew I bought DECK way too high. I bought VFC. It went up 75%. I decided not to sell any. It cratered back to where I bought it. That's why I sold my SHAK.
SHAK went up a lot, but I sold it. Is ROKU tech? Is Z tech? I hod both. My big risks are clothing (VFC, GOOS, DECK) and a phrama (VKTX).
can VKTX pump more so i can gtfo of these calls 😥
yo if LLY is going to buy VERV, can some biotech buy VKTX? and get this trash off my hands 😭
i’ve noticed that the SPX 0DTEs are on point; the individual stock callouts are dubious at best, however (especially VKTX)
(2/2) If you believe... * that the stock will calm back down by 7/18. * Check to see if simply letting the 6/20 expire worthless or rolling up and out to the 7/18 gives you more premium and do that (probably will be the 7/18 roll). * that the stock will continue to climb up to 7/18. * Eat the loss now because you do not want to have to pay more later to buy back to close your call option, especially because your main directive is to not lose the 100 shares to assignment. * you don't know. * The current expected move as derived from the options market is anywhere from +/- $6-$7 for the July 18 option chain. Meaning the option market predicts the price distribution for this time frame to fall between \~$22-$36 about 68 percent of the time. How badly are you willing to risk your 100 shares of $VKTX being called away for 34 bucks? * I'm assuming you don't want them called away because... * you have some analysis that implies they'll explode upward. If that's the case, your covered call is at odds with your main hypothesis, and you shouldn't be selling covered calls. * your cost basis for $VKTX is higher than any of these covered call strikes (even with premium helping to lower the overall cost basis), and thus you don't want them assigned away and locking in a loss. If THAT'S the case... I wanted you to have something before market open. Hopefully this didn't come out as nonsensical gibberish and is helpful, good night.
I've recently started trading options, limiting myself to covered calls and cash secured puts. I have 100 shares of VKTX and a 6/20 covered call for a $29 strike. Market closed at $29.14 today. Should I roll up and out now to 7/18 with a 32.50 strike for a credit of \~.34? Or should I wait until nearer the expiration? I don't want my holding to assign before expiration.
🚨🚨🚨 dont miss this life changing opportunity’ 🚨 Best Sub$20M Setup in the Entire Market? The obesity stock trend is just heating up and $GLMD might be the hidden gem everyone’s missing. We’ve already seen what happens when this theme catches fire $LLY, $HIMS, and $VKTX have all made lifechanging moves thanks to their exposure to the booming GLP-1 weight loss sector. But the one name no one’s watching yet is $GLMD and the setup here is insane. Tiny float (2.2M), over $6 cash per share, and a market cap under $5M… this is arguably the most asymmetric opportunity in the entire market right now. While others have already exploded, $GLMD is coiled and ready, with utilization nearing 100%, float locking underway, and a chart that screams “news is coming.” Shorts are starting to cover, but intraday shorting is surging meaning they’re running out of ammo fast. This is a classic float trap in progress. You’re not late… you’re early. This isn’t just undervalued it’s a loaded spring with GLP-1, NASH, and M&A potential all on deck. When it breaks out, it could be violent. This setup has everything low float, high short interest, insane valuation gap, and catalysts. It’s not just a trade… it’s a potential 1000% squeeze. Most people will laugh now, then chase it at $10+. That’s how it always goes. Let them call it a pump. Let them ignore it. I’ll bring eyes to this because it deserves attention and people deserve to catch it early. 💊 $LLY, $HIMS, and $VKTX already ran. $GLMD could be the final GLP-1 sleeper no one sees coming… yet.
VKTX is going to run up until the press conference in June.
Hope $VKTX gets bought out for a healthy sum by $PFE
Thanks, man! I’m mostly eyeing SGMT, IMTX, IOVA, CYTK, VKTX, and a few others further down the list. I’m keeping it to high-PoA plays, hedge-fund favorites, and SMID caps with at least \~15 months of cash. Always happy to chat - drop me a DM anytime!
Are you still holding? I'm thinking of opening a position soon or buying 2027 LEAPs. Data still looks very promising. VKTX is all or nothing. Phase 3 succeeds, they'll go over 100. Phase 3 fails, they'll go to 0.
Buy VKTX. But I wouldn’t listen to random people on the Internet.
VKTX is left… could be a banger in 3 months
I nibbled on LLY for that reason. Was considering NVO and/or VKTX as well.
No. That is the answer. Home equity doesn’t earn a return. Pay off $321K and you have $321K just sitting there. Sure you could invest the mortgage payment but that won’t (conservatively) earn you what you could earn on $321K LESS your monthly mortgage payment. Roll the dice on investing. You have plenty of safety nets. To each their own. If it was me — and because this is the investing board — I’d DCA into TGTX and VKTX for their big / long term prospects.
You considered listening to stock advice on Reddit? That’s so lame Buy VKTX
I’d invest. More specifically VKTX and TGTX. But don’t listen to random people on the internet. They are dumb.
Bols represent, what you buy today? I bought some VKTX
Just opened a long position on VKTX, don't make me regret it you pieces of shit 
VKTX performing well lately. PFE could be taking it out...
VKTX. PFE looking at an obesity acquisition/partnership again per earnings announcement
VKTX bull run starting up again
For all you DCA hoes… pay attention to upstarts with better molecules. You could easily have a situation with a company like VKTX announce unbelievable data and rip apart the thesis of NVO.
No longer have monopoly on weight loss....sooo...back to 2023 prices. Lilly shares are up 14.2% in response to the news, while shares of its rivals in the GLP-1 weight loss market, **Novo Nordisk** **(**[**NVO**](https://www.fool.com/quote/nyse/nvo/) \-6.89%**)** and **Viking Therapeutics** **(**[**VKTX**](https://www.fool.com/quote/nasdaq/vktx/) 0.51%**)**, are falling 7.1% and 1.7%
So the answer to what you would do as CEO today is: * buy VKTX after this jump * deeply slash the dividend
New CEO, new BD team and a detailed vision for the future of the company's M & A (PFE has been mediocre at best with capital allocation, leading to overpaying for some purchases like SGEN while others like GBT went badly - that drug was pulled from market and billions flushed) just for starters. A complete review of the state of the current pipeline and focusing on a few strengths, seeking opportunities to partner or sell anything else. In 2023, the company set a $10B target for obesity drug sales and then proceeded to have shit results for Danuglipron in December 2023 where they halted further study but kept going with an oral formulation which...just had further development halted after liver injury in a participant. Buy VKTX, which is substantially off highs and undervalued and get going on participating in obesity with something that works: I think if they bought that about 75% off highs, you'd actually see PFE go up nicely. (VKTX is up 17% pre-mkt after PFE's miss.) Biotech in general has been obliterated in recent months: refresh the pipeline, which clearly isn't exciting anyone (especially after another failure on obesity.) Cut the dividend. I remember once someone on WSB joked when asked what GE does, "they make dividends for old people." Pfizer feels similar - as long as the dividend keeps getting paid, the shareholder base doesn't really say much but underneath it's not a well-functioning company. The moment Immelt left GE and the dividend was cut, the spell was broken and people didn't like what they saw. Pfizer needs to be a better pharma company first and foremost and less a mediocre dividend play for undemanding investors who see a high yield and somehow don't pay any attention to an absymal record over the last couple decades.
VKTX up 18 percent premarket? Pfizer acquisition again?
Bought a bunch of VKTX calls ,why? Fuck me if i know
Bullish divergence on VKTX continues.. $25 entry was sweet yesterday. Oppenheimer slapped a 164 dollar target on it today, not that that means anything. But I still believe it could go parabolic
Bullish divergence on VKTX worked perfectly today
I love being a VKTX bagholder, I get to see high percentage swings every day
Textbook bullish divergence on VKTX, even with today's drop..So I went bottom fishing, opening a half position
its valled VKTX something in healthcare
its called VKTX something in healthcare
VKTX only green stock. I guess the buyout may be real, not sure
VKTX it has been a noose around my neck since Nov but finally showing signs of life after PFE rumors and initiation of a buyback program.
GOOGL and VKTX holding up the whole market 
Bourla talked about it. There are very few oral obesity drugs in late Stage 2. Data has been very good thus far. VKTX bounced hard off $24.50 low a few days ago
Go look at VKTX quickly. Seriously.
VKTX ..... PFE says in conference 2 days ago "looking at obesity drug acquisition" most other candidates have partnered up. Time to ask the last partner to dance 🕺 Let's Gooooo!! 🚀
PFE CEO Albert Bourla stated yesterday in a investor conference they have $10 billion and have interest in an oral obesity drug acquisition.....best one available is VKTX. It jumped $4 yesterday during conference. I'm buying. Could be worth $50-$60
VKTX is a big beautiful company and its stock price will go up to our great sky’s.